- Home
- NVA vs CMMB Comparison
NVA vs CMMB Comparison
Compare NVA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- CMMB
- Stock Information
- Founded
- NVA 1987
- CMMB 2004
- Country
- NVA Australia
- CMMB Israel
- Employees
- NVA N/A
- CMMB N/A
- Industry
- NVA
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- NVA
- CMMB Health Care
- Exchange
- NVA NYSE
- CMMB Nasdaq
- Market Cap
- NVA 24.4M
- CMMB 20.9M
- IPO Year
- NVA N/A
- CMMB N/A
- Fundamental
- Price
- NVA $7.43
- CMMB $1.28
- Analyst Decision
- NVA
- CMMB Strong Buy
- Analyst Count
- NVA 0
- CMMB 3
- Target Price
- NVA N/A
- CMMB $5.67
- AVG Volume (30 Days)
- NVA 66.5K
- CMMB 157.1K
- Earning Date
- NVA 01-01-0001
- CMMB 11-07-2024
- Dividend Yield
- NVA N/A
- CMMB N/A
- EPS Growth
- NVA N/A
- CMMB N/A
- EPS
- NVA N/A
- CMMB N/A
- Revenue
- NVA N/A
- CMMB N/A
- Revenue This Year
- NVA N/A
- CMMB N/A
- Revenue Next Year
- NVA N/A
- CMMB N/A
- P/E Ratio
- NVA N/A
- CMMB N/A
- Revenue Growth
- NVA N/A
- CMMB N/A
- 52 Week Low
- NVA $4.35
- CMMB $0.42
- 52 Week High
- NVA $7.70
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- CMMB 40.12
- Support Level
- NVA N/A
- CMMB $1.09
- Resistance Level
- NVA N/A
- CMMB $1.39
- Average True Range (ATR)
- NVA 0.00
- CMMB 0.17
- MACD
- NVA 0.00
- CMMB -0.02
- Stochastic Oscillator
- NVA 0.00
- CMMB 27.54
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a minerals explorer and developer focused on gold and lithium projects in North America. It has a diversified portfolio of projects across the US, Canada, and Australia. Its key projects include Nova's 6.2Moz Estelle Gold Project on Korbel Main and RPM in Alaska, which holds some of North America's largest gold deposits, and the company's majority-owned Snow Lakes Resources, a proposed zero carbon lithium spodumene project in Canada ideally located on rail access to the US Auto Alley. Nova aims to provide shareholders with diversification through exposure to base and precious metals and to capitalize on the growing demand for lithium-based energy storage.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.